Susceptibility of human breast epithelial cells in vitro to hormones and drugs

International Journal of Oncology

Volumn 28, Issue 2, 2006, Pages 285-295

  Calaf, Gloria M ^a,b  

^a NewYork Presbyterian Hospital   (United States)

^b UNIVERSIDAD DE TARAPACÁ   (Chile)

Author keywords

Breast; Estrogen; Progesterone; Proliferation; RU486; Tamoxifen

Indexed keywords

ANTIESTROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ESTRADIOL; GESTAGEN; MIFEPRISTONE; PROGESTERONE; TAMOXIFEN;

ARTICLE; BREAST; BREAST TUMOR; CELL PROLIFERATION; DRUG EFFECT; EPITHELIUM CELL; FEMALE; HUMAN; ORGAN CULTURE TECHNIQUE; PAGET NIPPLE DISEASE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIAL CELLS; ESTRADIOL; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; MIFEPRISTONE; ORGAN CULTURE TECHNIQUES; PROGESTERONE; PROGESTINS; TAMOXIFEN;

EID: 34547481699     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.2.285     Document Type: Article

References (60)

1. Krieger N: Exposure, susceptibility, and breast cancer risk: a hypothesis regarding exogenous carcinogens, breast tissue development, and social gradients, including black\white differences, in breast cancer incidence. Breast Cancer Res Treat 13: 205-223, 1989.
2. Henderson BE, Ross R and Bernstein L: Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture. Cancer Res 48: 246-253, 1988.
3. Feigelson HS, Ross RK, Yu MC, Coetzee GA, Reichardt JK and Henderson BE: Genetic susceptibility to cancer from exogenous and endogenous exposures. J Cell Biochem Suppl 25: 15-22, 1996.
4. Henderson BE, Ross RK and Pike MC: Hormonal chemoprevention of cancer in women. Science 259: 633-638, 1993.
5. Huseby RA: Methods in Hormone Research. Dorfman RV (ed). Academic Press, New York, p123, 1965.
6. Dickson RB and Lippman ME: Estrogenic regulation of growth and polypeptide growth factor secretion in human breast carcinoma. Endocr Rev 8: 29-43, 1987.
7. Petrakis NL, Ernster VL and King MC: Breast. In: Cancer Epidemiology and Prevention. Schottenfeld D and Fraumeni JF Jr (eds). WB Saunders, Philadelphia, pp855-870, 1982.
8. Jordan VC: Chemoprevention in the 21st century: is a balance best or should women have no estrogen at all? J Clin Oncol 23: 1598-1600, 2005.
9. Cole MP, Jones CT and Todd ID: A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer 25: 270-275, 1971.
10. Tormey DC and Jordan VC: Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study. Breast Cancer Res Treat 4: 297-302, 1984.
11. Tormey DC: Long-term adjuvant therapy with tamoxifen in breast cancer: how long is it? Ann Intern Med 106: 762-764, 1987.
12. Early Breast Cancer Trial List' Collaborative Group: Effects of adjuvant tamoxifen and of cytotoxic therapy in early breast cancer: an overview of 61 randomized trails among 28,896 women. N Engl J Med 319: 1681-1692, 1988.
13. Jordan VC: Long-term adjuvant tamoxifen therapy. In: Important Advances in Oncology. De Vita UT, Hellman S and Rosemberg SA (eds). Lippincott, Philadelphia, 1989.
14. Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions. J Med Chem 46: 883-908, 2003.
15. Jordan VC: Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents. J Med Chem 46: 1081-1111, 2003.
16. Fisher B, Bryant J, Digman JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM and Wolmark N: Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20: 4141-4149, 2002.
17. Moguilewsky M and Philibert D: RU 38486: potent antiglucocorticoid activity correlated with strong binding to the cytosolic glucocorticoid receptor followed by and impaired activation. J Steroid Biochem 20: 271-276, 1984.
18. Philibert D, Moguilewsky M, Mary I, Lecque D, Touremine C, Secchi J and Deraedt R: Pharmacological profile of RU 486 in animals. In: The Antiprogestin Steroid RU 486 and Human Fertility Control. Baulieu E-E (ed). Plenum Publishing Co., New York, pp49-68, 1985.
19. Rauch M, Loosfelt H, Philibert D and Milgrom E: Mechanism of action of an antiprogesterone, RU486, in the rabbit endometrium. Effects of RU486 on the progesterone receptor and on the expression of the uteroglobin gene. Eur J Biochem 148: 213-218, 1985.
20. Spitz IM and Bardin CW: Mifepristone (RU 486) a modulator of progestin and glucocorticoid action. N Engl J Med 329: 404-412, 1993.
21. Spitz IM: Progesterone antagonist and progesterone receptor: an overview. Steroids 68: 981-993, 2003.
22. Stampfer M, Hallowes RC and Hackett AJ: Growth of normal human mammary cells in culture. In Vitro 16: 415-425, 1980.
23. Calaf G, Russo IH, Roi L and Russo J: Influence of age on DNA labeling index of human breast epithelium. IRCS Med Sci 10: 657-658, 1982.
24. Calaf G, Russo IH and Russo J: Effects of peptides and steroid hormones on cell kinetic parameters of normal human tissue in organ culture. In Vitro Cell Dev Biol 22: 135-140, 1986.
25. Calaf G, Garrido F, Moyano C and Rodriguez R: Influence of hormones on DNA synthesis of breast tumors in culture. Breast Cancer Res Treat 8: 223-232, 1986.
26. Soule HD, Maloney TM, Wolman SR, Petersen WD Jr, Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF and Brooks SC: Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res 50: 6075-6086, 1990. (Pubitemid 20331424)
27. Calaf G, Russo J, Tait L, Estrada S and Alvarado ME: Morphological phenotypes in neoplastic progression of human breast epithelial cells. J Submicrosc Cytol Pathol 32: 83-96, 2000.
28. Calaf G, Russo J and Alvarado ME: Morphological phenotypes in neoplastic progression of benz(a)pyrene-treated breast epithelial cells. J Submicrosc Cytol Pathol 32: 535-545, 2001.
29. Calaf G and Russo J: Transformation of human breast epithelial cells by chemical carcinogens. Carcinogenesis 14: 483-492, 1993.
30. Soule HD, Vazguez J, Long A, Albert S and Brennan M: A human cell line from a pleural effusion derived from a breast carcinoma. J Natl Cancer Inst 51: 1409-1416, 1973.
31. Calaf G and Hei TK: Establishment of a radiation- and estrogen-induced breast cancer model. Carcinogenesis 21: 769-776, 2000.
32. Russo J and Russo IH: DNA-labeling index and structure of the rat mammary gland as determinants of its susceptibility to carcinogenesis. J Natl Cancer Inst 61: 1451-1459, 1978.
33. Russo J and Russo IH: Influence of differentiation and cell kinetics on the susceptibility of the rat mammary gland to carcinogenesis. Cancer Res 40: 2677-2687, 1980.
34. Russo J and Russo IH: Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 3: 353-364, 1994.
35. Russo J, Calaf G, Roi L and Russo IH: Influence of age and gland topography on cell kinetics of normal human breast tissue. J Natl Cancer Inst 78: 413-418, 1987.
36. Calaf G, Russo IH, Roi L and Russo J: Effect of estrogen on the length of S phase of human breast tissue. IRCS Med Sci 10: 307-308, 1982. (Pubitemid 12152251)
37. Calaf G, Russo IH, Roi L and Russo J: Effect of hormones on growth fraction of human breast tissue in organ culture. IRCS Med Sci 10: 655-656, 1982. (Pubitemid 12046188)
38. Welsch CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: a review and tribute to Charles Brenton Huggins. Cancer Res 45: 3415-3443, 1985.
39. Bernstein L, Depue RH, Ross RK, Judd HL, Pike MC and Henderson BE: Higher maternal levels of free estradiol in first compared to second pregnancy: early gestational differences. J Natl Cancer Inst 76: 1035-1039, 1986.
40. Hadjimichael OC, Boyle CA and Meigs JW: Abortion before first livebirth and risk of breast cancer. Br J Cancer 3: 281-284, 1986.
41. Pike MC, Henderson BE, Casagrande JT, Rosario I and Gray GE: Oral contraceptive use and early abortion as risk factor for breast cancer in young women. Br J Cancer 43: 72-76, 1981.
42. Potten CS: Stem Cells. Their Identification and Characteristics. Churchill-Livingstone, Edinburgh, 1983.
43. Loeb LA: Mutator phenotype may be required for multistage carcinogenesis. Cancer Res 51: 3075-3079, 1991.
44. Bernstein L and Ross RK: Endogenous hormones and breast cancer risk. Epidemiol Rev 15: 48-65, 1993.
45. Henderson BE, Pike MC and Ross RK: Epidemiology and risk factors. In: Breast Cancer: Diagnosis and Management. Bonadonna G (ed). John Wiley and Sons, Ltd., New York, 1984.
46. Lippman ME, Osborne CK, Knazek R and Young N: In vitro model systems for the study of hormone-dependent human breast cancer. N Engl J Med 296: 154-159, 1976.
47. Dickson MB and Lippman ME: Control of human breast cancer by estrogen, gene factors and oncogenes. In: Breast Cancer: Cellular and Molecular Biology. Lippman ME and Dickson RB (eds). Kluwer Academic, Norwell, MA, pp119-166, 1988.
48. Siiteri PK, Hammond GL and Nisker JA: Increased bioavailabitity of serum estrogens in breast cancer: a new hypothesis. In: Hormones and Breast Cancer, Banbury Report 8. Pike MC, Siiteri PK and Welsch CW (eds). Cold Spring Harbor Laboratory, New York, 1981.
49. Fentiman IS: Detection and Treatment of Early Breast Cancer. JB Lippincott, Philadelphia, 1990.
50. Preston-Martin S, Pike MC, Ross RK, Jones PA and Henderson BE: Increased cell division as a cause of human cancer. Cancer Res 50: 7415-7421, 1990.
51. Cairns J: Mutation selection and the natural history of cancer. Nature 255: 197-200, 1975.
52. Welshons WV, Murphy CS, Kock R, Calaf G and Jordan VC: Stimulation of breast cancer cells in vitro by the environmental estrogen, enterolactone and the phyto-estrogen equol. Breast Cancer Res Treat 10: 169-175, 1987.
53. Calaf G, Abarca-Quiñones J, Feuilhade F, Beaune J, Dupre G, Orrico M, Barnabas-Sohi N and Kouyoumkjian JC: New cell lines of human breast cancer origin. Breast Cancer Res Treat 21: 63-75, 1992.
54. Henderson BE, Ross RK, Pike MC and Casagrande JT: Endogenous hormones as a major factor in human cancer. Cancer Res 42: 3232-3239, 1982.
55. Furr BJ and Jordan VC: The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25: 127-205, 1984.
56. Nicholson RI, Gotting KE, Gee J and Walker KJ: Actions of oestrogens and anti-oestrogens on rat mammary gland development: relevance to breast cancer prevention. J Steroid Biochem 30: 95-103, 1988.
57. Gotze S, Nishino Y and Neumann F: Anti-oestrogenic effects of tamoxifen on mammary gland and hypophysis in female rats. Acta Edocrinol Copenh 105: 360-370, 1984.
58. Jordan VC: Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208: 144-149, 1995.
59. Murphy LC, Peng B, Lewis A, Davie JR, Leygue E, Kemp A, Ung K, Vendetti M and Shiu R: Inducible upregulation of oestrogen receptor-{beta}1 affects oestrogen and tamoxifen responsiveness in MCF7 human breast cancer cells. J Mol Endocrinol 34: 553-566, 2005.
60. Calaf G and Hei TK: Oncoprotein expressions in human breast epithelial cells transformed by high LET radiation. Int J Radiat Biol 77: 31-40, 2001. (Pubitemid 32096694)